Frith, Peter A <br/><br/>
Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial.  [electronic resource] 

 -  Thorax  Jun 2015 
 - 519-27 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1468-3296 
<br/><br/><label>Standard No.: </label>10.1136/thoraxjnl-2014-206670  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Inhalation<br/>Aged<br/>Albuterol--analogs & derivatives<br/>Androstadienes--therapeutic use<br/>Australia<br/>Bronchodilator Agents--therapeutic use<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Drug Administration Schedule<br/>Drug Therapy, Combination<br/>Female<br/>Fluticasone<br/>Forced Expiratory Volume--drug effects<br/>Glycopyrrolate--therapeutic use<br/>Health Status<br/>Humans<br/>Male<br/>Middle Aged<br/>New Zealand<br/>Pulmonary Disease, Chronic Obstructive--diagnosis<br/>Risk Factors<br/>Salmeterol Xinafoate<br/>Scopolamine Derivatives--therapeutic use<br/>Severity of Illness Index<br/>Surveys and Questionnaires<br/>Tiotropium Bromide<br/>Treatment Outcome